Teclistamab and Mezigdomide
Teclistamab and Mezigdomide for Relapsed/Refractory Multiple Myeloma
What's the purpose of the trial?
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
Trial status
Accepting patients
Phase
Phase 1
Enrollment
18
Last Updated
3 days ago
Participating Centers
There are 7 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Mezigdomide is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.
- Teclistamab is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.